In response to RFA CA-07-048, Community Clinical Oncology Program, National Cancer Institute, the Carle Cancer Center, Urbana, Illinois is applying for continued funding as a CCOP in East Central Illinois. As the largest private medical group practice in Illinois, with 334 physicians, the Carle Clinic Association has a fully developed cancer center program which has been involved in national clinical trial research since 1976. The Carle Cancer Center has been continuously funded as a CCOP since the program's inception in 1983. Joining Carle in this CCOP application as component institutions are Rush- Copley Medical Center in Aurora, Illinois, Joliet Oncology-Hematology Associates in Joliet, Illinois, and St. Anthony Memorial Health Center, in Michigan City, Indiana. The combined Carle Cancer Center CCOP provides services to cancer patients within a catchment area of 32 counties in east central Illinois and western Indiana, 10 counties south and southwest of Chicago, and 4 counties in northwestern Indiana. The primary center of operations for the CCOP is located at the Carle Cancer Center with all randomizations, administration, and quality assurance programs managed in Urbana, Illinois. The CCOP's primary research base is the North Central Cancer Treatment Group. There are also strong affiliations with the Eastern Cooperative Oncology Group and the National Surgical Adjuvant Breast and Bowel Project. Additionally, new affiliations were established with the Cancer Trials Support Unit in 2003 and with the Gynecologic Oncology Group in 2004. The Carle Cancer Center and its affiliates have dedicated clinical research professionals, nurses, and administrative staff to assist a multidisciplinary physician team in clinical trials that result in an average of 174 treatment credits and 260 cancer control/prevention credits annually. The goal of the Carle Cancer Center CCOP is to offer and facilitate a wide range of cancer treatment and prevention opportunities to individuals within their communities. The CCOP is dedicated to reducing cancer incidence and mortality through ongoing scientific research and to applying knowledge from research in ways that benefit all patient populations. The Carle Cancer Center CCOP believes that it is vital to maintain participation in cancer treatment and prevention clinical trials in order to provide the highest standard of cancer care to present patients and the best possible hope to future generations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035195-29
Application #
8324133
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Kelaghan, Joseph
Project Start
1990-06-01
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
29
Fiscal Year
2012
Total Cost
$728,213
Indirect Cost
$100,745
Name
Carle Foundation
Department
Type
DUNS #
075606517
City
Urbana
State
IL
Country
United States
Zip Code
61801
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Schild, Michael H; Schild, Steven E; Wong, William W et al. (2014) Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. OMICS J Radiol 3:
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005

Showing the most recent 10 out of 164 publications